News & Events

Lucence Presents Data at ESMO 2021 Showing Liquid Biopsy Detects Actionable Genomic Alterations in Bladder Cancer Patients Undergoing Immunotherapy

Lucence Announces Commercial Availability of Tissue500™ for Comprehensive Targeted Therapy Matching

Lucence Presents Real-World Evidence on Applications of Liquid Biopsy at 2021 ASCO, Announces Formation of Medical Advisory Board

Lucence Launches US Validation Study for LiquidHALLMARK® Liquid Biopsy Test for Biomarker Detection in Lung Cancer

Lucence Partners with Waseda University to Develop an Integrated Liquid Biopsy Platform for Cancer Screening

Lucence Receives CLIA Certification for US Laboratory, Expands Access to Amplicon-Based Liquid Biopsy Tests

Lucence Shares Data at ASCO20 Demonstrating High Sensitivity of AmpliMARK™ Sequencing Technology in Detecting Clinically Relevant Biomarkers in Lung Cancer

Lucence Presents Data Demonstrating Potential of AmpliMARK™ Powered Sequencing to Detect Genomic Alterations at High Sensitivity in Blood Cancers